Lilly Bamlanivimab Antibody Playbook
This antibody playbook provides information for state, territorial and local public health programs to plan and operationalize a bamlanivimab antibody response to COVID-19. The sections of this document cover specific areas of COVID-19 antibody program planning and implementation, as well as links to resources to assist with those efforts.
Related Content
Resources for IV Fluid Mitigation
CHA Submits Letter to HHS on Baxter Closure
The Life-Saving Potential of High-Cost Therapies
Resources for IV Fluid Mitigation
CHA is sharing information from children’s hospitals and industry experts to help address IV fluid disruption in the wake of Hurricane Helene.
CHA Submits Letter to HHS on Baxter Closure
The letter thanks HHS for their response to supply shortages caused by Hurricane Helene and urges continued support for pediatric needs during ongoing IV solution shortages.
The Life-Saving Potential of High-Cost Therapies
HCTs can address gaps in care and health disparities, offering life-changing treatments and potential cures for complex and rare conditions once deemed untreatable.
